MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, August 29, 2009

A report from Italy on Stem Cells and Multiple Sclerosis

Published .

“Gianvito Martino, the head of the Neurosciences division at the Institute of San Raffaele in Milan in a speech at Multiple Sclerosis Week, which took place from May 23-31, warned against “trips of hope to clinics that promise effective treatments using stem cells”.

According to Martino, who coordinated a Consensus Conference on last Tuesday in London on theneurodegenerative disease, where the guidelines for pre-clinical studies and clinical treatments with stem cells were defined, “hundreds of Italian patients each year go on these trips due to cures that are promised. In the best-case scenario, these patients return in the same condition in which they departed, but with a little bit less money. However, there are also many cases of infections and tumors.”

These stem cell clinics are found in various countries all over the world, including China, Thailand, the Dominican Republic, Manila, and Barbados. “They assure 40%-50% effectiveness and that they are able to treat any type of problem, from baldness to Alzheimer’s as well as muscular sclerosis, but they do not say anything about the type and quality of stem cells that they use. They use the placebo effect to indicate very few positive outcomes, but in the end, no one knows what is responsible for the cures.” Martino thinks that in many cases patients are given water instead of stem cells, or cortisone in order to give a few days of perceived improvements and to feed the illusion.


Friday, August 28, 2009

Norwood Hospital to offer schooling on MS

Daily News Transcript
Posted Aug 28, 2009

Norwood -- Experts in the treatment of multiple sclerosis will provide insight into the complex neurological and autoimmune disease in a six-part lecture series at Norwood Hospital.

"This is an opportunity for us to give the public some new information on therapies and on symptom management, and updates of symptom therapy," said Dr. Salvatore Napoli, neurologist and medical director of the hospital's Multiple Sclerosis Center.

Multiple sclerosis is a chronic illness that affects the brain and spinal cord, resulting in loss of muscle control, vision, balance and sensation. More than 400,000 Americans have MS, including as many as 1,300 Norfolk County residents, according to the New England Chapter of the National Multiple Sclerosis Society.

Continue reading Schooling on MS

If not yet receiving the Stu's Views and MS Related News, weekly e-newsletter, then please click here to register. This process will take less than 25 seconds to complete.



Treatment Worse than MS ??? - part 2

On August 18th, I posted an article from our Ask an MS Nurse, that has drawn several comments (posted on this blog) several others that posted their replies on Facebook and yet a few more who just had to send their remarks directly to me .

If you click this link: Treatment Worse than MS?" , you will have access to the original article posting.

Maybe you missed seeing it the first time, maybe you wanted to leave a comment and felt timid.
Now, you can read what others have said (that posted to this blog link) and if you want to comment, then please do so...

For those using facebook, please leave any comments that you may have for the original posting, by clicking on the link found above.

Thank You


MS Related: Generic versions of biologic medications are coming

Aug 28, 2009, 4:57 p.m. EST
Companies most likely to produce biogenerics

By Val Brickates Kennedy, MarketWatch

BOSTON (MarketWatch) -- The days of market exclusivity could soon come to an end for the biotech industry if Congress moves forward with plans to finally allow generic biologics on the U.S. market.

Because of their eye-popping price tags, pressure to rein in the cost of biologics has been mounting on Capitol Hill for some time. A process for approving generic versions of traditional chemical medications has been in place for more than a decade, but Congress has yet to establish a similar legal pathway for biologics.

But all that could change in the next few months. Currently, almost all of the leading healthcare reform bills circulating on the Hill call for allowing the Food and Drug Administration to establish an approval process for generic biologics, also known as biogenerics or biosimilars.

Continue reading


Thursday, August 27, 2009

New MobilityMagazine oulook on Facebook

This mentionable note appears in the September issue of New MobilityMagazine:

Why Does Facebook Matter?
For one thing, just about everyone’s doing it. A recent New Mobility survey determined that more than 70 percent of our readers have Facebook accounts. While Facebook is sweeping the mainstream population as well, those with disabilities are finding ways of connecting that just didn’t exist before. If not for social networking or advocacy, then perhaps for purposes of marketing, self-expression, or finding those long lost classmates. Whatever the reason people get drawn into the Facebook culture, one thing is for sure: The term ‘friend’ is being redefined in ways no one could have imagined just a few short years ago.

Find MS Views and News on Facebook's join our cause


HAVE Multiple Sclerosis? Work out -- as though your life depends on it

Posted: Thursday, August 27, 2009 12:50 am

Alan Worth is at the gym Tuesday afternoon, a guy faithful to his workouts.

He was a slacker -- a couch potato, self-described -- back when when he was practicing family medicine.

Now he's organized a twice-a-week class at the Cooper YMCA. Proposed it. Promoted it. Solicited money for it.

The class began three weeks ago and meets every Tuesday and Thursday at 4. A few people arrive in scooters. One man walks with a cane.

Alan uses a cane sometimes, too.

He was diagnosed with multiple sclerosis four years ago. He'd been tripping over his feet, thought he was just clumsy.

Instead, he found out he has a slow but progressive form of the disease, which blocks nerve impulses to different parts of the body.

Click here to read more on: working out with MS.


Mind Over Matter: Computer games challenge people with MS


A nimble stick man strolls along a cyber street on a hunt for words that fall into the category “vegetable.” With a few taps on a keyboard, he is sent leaping into the air to grab balloons labeled with suitable words, such as “peas,” “okra” and “squash.”

Along the way, he “ignores” decoy balloons with words like “door” and “mask” to keep from losing points. He also ducks to miss low-hanging balloons and jumps over rocks to avoid deductions.

That's “Round-Up,” one of three games in a free, online suite of computer games that Dr. Stephen Kirzinger of the University of Louisville has helped create for multiple sclerosis patients.

The suite, called MyBrainGames, is an outgrowth of the MS Technology Collaborative, a joint project of Microsoft, the National Multiple Sclerosis Society and Bayer HealthCare Pharmaceuticals.

Continue to read from the 5th paragraph: Computer mind games for People with MS


Wednesday, August 26, 2009

Multiple Sclerosis advertisements from around the world


It's always fascinating to see how people see Multiple Sclerosis around the world, and here are a few amazing clips of advertisements and commercials...

View global MS advertisements


If not yet receiving our weekly MS related e-newsletter (published each Thursday), then please visit our website to register:
Thank you


Tuesday, August 25, 2009

Changing Healthcare from the Ground Up

Reforming healthcare is headline news
these days. It’s a highly contentious
topic-- probably the only place where
there is agreement is that it’s a huge
problem that will take time to fix.

At the Rocky Mountain MS Center,
we would like to propose a more
immediate place to start.
A personal health record is simply a
collection of the important information
about you and your health concerns,
compiled by the person who knows
the most about it—you. It contains the
information you need to verify accuracy,
avoid duplication, ensure continuity
of care, and provide easy and portable
access to the data you need to make
informed healthcare decisions and put
you and your healthcare
provider on the same page.

Continue reading this import healthcare information
on page 2


Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**

ue Aug 25, 10:00 am ET

Companies Announce a Collaboration for the Development of AMP-110 - An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases

New York, NY/Rockville, MD (Vocus) August 25, 2009 -- Amplimmune, Inc., a Maryland-based biotechnology company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a collaboration to support the development of Amplimmune's AMP-110 therapeutic candidate. This novel and proprietary biological molecule, or biologic, is specifically designed to target and prevent the abnormal immune responses associated with multiple sclerosis and other autoimmune diseases.

The agreement with Amplimmune is the third in a series of growing partnerships between Fast Forward and emerging biotechnology companies. "We are pleased to partner with Amplimmune to advance the development of new treatments for MS," said Dr. Timothy Coetzee, President of Fast Forward. "AMP-110 represents an important inventive approach to inhibiting inflammatory responses in multiple sclerosis." Adds Dr. Coetzee, "Modulating the immune system by using costimulatory and coinhibitory biologics is an active area of research and has significant potential in developing new therapies for MS. AMP-110 fits our profile for supporting innovative and promising new treatments for MS."

Read more on To Speed New Treatments for MS


Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients,

  • Source: Peptimmune, Inc.
  • On Tuesday August 25, 2009

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized study enrolled 50 subjects with SP-MS. A total of 36 subjects received PI-2301 once weekly for 8 weeks followed by an open label extension of an additional 4 weeks. The doses ranged from 1 to 60 mg. Safety at all doses, including potentially therapeutic doses, was established. The most frequent adverse events (AEs) were dose-dependent site reactions which were mild to moderate, transient, and resolved without specific therapy. Dose-dependent increases in serum levels of anti-inflammatory markers were consistent with PI-2301 exposure as measured using the Company's proprietary pharmacokinetic assay. The Company plans to continue developing this promising compound by initiating a Phase II study in multiple sclerosis patients later this year.

Read more on PI-2301 peptide copolymer


News Release: Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS

  • Peripheral and Central Nervous System Drugs Advisory Committee to Hold Meeting on October 14, 2009
  • Proposed Trade Name for Fampridine-SR, if approved, is Amaya™

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 25, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009. The meeting will take place at the Inn and Conference Center, University of Maryland University College (UMUC), Marriott Conference Centers, 3501 University Blvd. East, Adelphi, MD. Information related to the meeting is available on the U.S. Office of the Federal Register web site at:

The Company also announced that it has received preliminary approval for the proposed trade name Amaya from the FDA.

Fampridine-SR is a novel therapy being studied as a potential treatment to improve walking ability in people with multiple sclerosis. The Fampridine-SR NDA was accepted by the FDA on May 5, 2009 and assigned Priority Review status. At that time, the FDA set a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009; the PDUFA date is the target date for the FDA to complete its review of Fampridine-SR.

About Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR is being developed by Acorda Therapeutics and manufactured by Elan Corporation plc.

click here to read more of Fampridine -SR

Monday, August 24, 2009

Bristol Scientists Make Major MS Breakthrough

Monday August 24, 2009

A dramatic step forward in the treatment of Multiple Sclerosis has been made by scientists at the University of Bristol, which could help to slow down or even stop the development of the crippling disease in thousands of patients worldwide.

Research on a protein which occurs more frequently in sufferers of MS was tested by a team led by David Wynick, professor of molecular medicine at the university, and found to make laboratory mice "completely resistant" to a disease similar to MS.

Work on developing a drug has now started, although it could be 10 years before a treatment is available for patients and will require tens of millions of pounds to fund.

Explaining the research, Professor Wynick said: "The levels of a protein called galanin are much higher in the brains of patients with MS. We weren't sure why that was, so we used an animal model of MS and showed that if we increase the levels of this protein in the brains of mice they are completely resistant to the development of the disease.

"So we concluded that in MS patients, the levels of protein are elevated because it is trying to protect the brain from damage. We don't know why it happens, but it is a terrible disease and anything we can do that slows down or stops its progression will be a major step forward."

CLICK this, to continue to READ


Sunday, August 23, 2009

Who is Help Resources?

We are just trying to make a difference in this little world around us. Trying to pay it forward so to say, and give some hope to those that are a bit down on their luck, or just having a hard time in their lives for one reason or another.

Our goal is to help provide the necessary information and access to resources to help people better whatever the tough situation is they are finding themselves in. And the web is a great way to do that. So to that end we will be devoting extensive resources, and will continue to branch into additional areas as our resources allow us to. We firmly believe in helping empower people to pick themselves up by their "boot straps" and make things better for themselves and those they care for.

Click the Logo to learn more

Internet Resources for those affected by Multiple Sclerosis (MS)

Are you receive the weekly published Multiple Sclerosis e-Newsletter, "Stu's Views and MS Related News" ? If not, click this link to register. This will enable you to be amongst those from (53) Countries who are already receiving this empowering information each week.